[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
Aug 2011

Use of Mitoxantrone in Neuromyelitis Optica—Reply

Author Affiliations

Author Affiliations: Department of Neurology, Research Institute and Hospital of National Cancer Center, Gyeonggi-do, South Korea.

Arch Neurol. 2011;68(8):1086-1087. doi:10.1001/archneurol.2011.171

In reply

We thank Kitley and colleagues for their interest in our article and their comments. All patients described in our article1 were referred to our center from other hospitals owing to frequent relapses despite treatment. In fact, many of them were treated with interferon beta after a diagnosis of optic-spinal multiple sclerosis. As Kitley and colleagues pointed out, based on the recent studies,2,3 treatment with interferon beta might have contributed to the high pretreatment relapse rate, which could have made mitoxantrone treatment appear more efficacious in our study. However, what we want to emphasize is that 6 cycles of mitoxantrone induction treatment effectively suppressed the highly active disease status, even if it might result from inappropriate treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×